SCHEDULE: RTW Investments Maintains Key Taysha Gene Stake

RTW Investments and Roderick Wong report a 9.9% beneficial ownership stake in Taysha Gene Therapies, Inc., holding over 25 million shares.

Summary

• RTW Investments, LP and Roderick Wong collectively report beneficial ownership of 25,183,287 shares of Taysha Gene Therapies, Inc. Common Stock.
• This ownership represents 9.9% of the company's outstanding shares.
• The percentage is calculated based on 251,923,257 shares outstanding as of May 30, 2025, as reported in the company's prospectus supplement dated May 28, 2025.
• The reported beneficial ownership includes the assumption of exercising warrants to purchase 161,703 shares.
• RTW Investments, LP serves as the investment adviser to certain funds (the "RTW Funds") that directly hold the shares.
• Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW Investments.
• RTW Master Fund Ltd., an RTW Fund, has the right to receive or direct dividends or proceeds from the sale of more than 5% of the Shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine ownership disclosure, but the maintenance of a significant stake by a specialized investor like RTW Investments can be seen as a positive signal of confidence in the company's long-term prospects, despite the 9.99% ownership cap.

Positives

• A significant institutional investor, RTW Investments, maintains a substantial 9.9% stake, indicating continued confidence in Taysha Gene Therapies.
• The beneficial ownership includes warrants, suggesting potential for future capital deployment or increased stake if ownership limitations allow.

Negatives

• The 9.99% beneficial ownership cap on warrant exercise limits the immediate upside from warrant conversion for the reporting persons.

Risks

• The Reporting Persons are restricted by warrant terms from exercising warrants if it would cause their beneficial ownership to exceed 9.99% of the outstanding shares.

Future Outlook

Not applicable, as this filing is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates continued significant institutional investment in the gene therapy sector, specifically in Taysha Gene Therapies, a company focused on developing gene therapies. Such substantial stakes by specialized investment firms like RTW Investments often signal perceived long-term value or strategic interest within the high-growth, high-risk biotechnology industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Company Management: Awareness of a large, active shareholder may influence strategic decisions or communication.

Key Dates

Keywords

Taysha Gene Therapies, RTW Investments, Roderick Wong, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Investment, Warrants